The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis
Authors:
- 1 October 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 6 (5) , 481-492
Abstract
Chronic obstructive pulmonary disease is a common condition which causes considerable morbidity and mortality. It is a heterogenous disorder in which the majority of patients have chronic bronchitis. Bacterial infections are a major cause of acute exacerbations of both conditions which have a major impact on healthcare resources, quality of life and disease progression. Antibiotics are used to treat exacerbations involving purulent sputum production, together with increased breathlessness and/or sputum volume. Moxifloxacin is a quinolone antibiotic and is one of the treatment options. This article discusses pathophysiology of these diseases, moxifloxacin clinical studies and appropriate use of moxifloxacin.Keywords
This publication has 68 references indexed in Scilit:
- Moxifloxacinversusamoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL resultsEuropean Respiratory Journal, 2011
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Prevention of exacerbations of COPD with pharmacotherapyEuropean Respiratory Review, 2010
- Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trialRespiratory Research, 2010
- Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT studyTherapeutic Advances in Respiratory Disease, 2009
- Safety Profile of the Respiratory Fluoroquinolone MoxifloxacinDrug Safety, 2009
- Quinolone-Mediated Bacterial DeathAntimicrobial Agents and Chemotherapy, 2008
- International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence studyThe Lancet, 2007
- Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary diseaseThorax, 2007
- Retrospective Analysis of the Safety Profile of Oral Moxifloxacin in Elderly Patients Enrolled in Clinical TrialsDrug Safety, 2005